期刊
NATURE REVIEWS DRUG DISCOVERY
卷 18, 期 3, 页码 175-196出版社
NATURE PORTFOLIO
DOI: 10.1038/s41573-018-0006-z
关键词
-
资金
- Burroughs Wellcome Fund Career Award at the Scientific Interface
- US National Institutes of Health (NIH) Director's New Innovator Award [DP2 TR002776]
- American Cancer Society [129784-IRG-16-188-38-IRG]
- NIH T32 multidisciplinary training grant
- Cancer Center Support (core) Grant from the US National Cancer Institute [P30-CA14051]
- Koch Institute's Marble Centre for Cancer Nanomedicine
Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical and preclinical development. However, a key challenge in the broad implementation of immunotherapies for cancer remains the controlled modulation of the immune system, as these therapeutics have serious adverse effects including autoimmunity and nonspecific inflammation. Understanding how to increase the response rates to various classes of immunotherapy is key to improving efficacy and controlling these adverse effects. Advanced biomaterials and drug delivery systems, such as nanoparticles and the use of T cells to deliver therapies, could effectively harness immunotherapies and improve their potency while reducing toxic side effects. Here, we discuss these research advances, as well as the opportunities and challenges for integrating delivery technologies into cancer immunotherapy, and we critically analyse the outlook for these emerging areas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据